Midday Report: Lyra (LYRA) Shares Climb for August 5

Equities Staff  |

Lyra Therapeutics Inc (NASDAQ: LYRA) shares moved 8.60%, or $0.51 per share, as on 11:59:21 est today. After Opening the Day at $6.20, 10,431 shares of Lyra have exchanged hands and the stock has ranged between $6.44 and $6.20.  

So far this year the company is up 42.89%.

Lyra expects its next earnings on 2022-08-08.

For technical charts, analysis, and more on Lyra visit the company profile.

About Lyra Therapeutics Inc

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases. The company's lead product candidate, LYR-210, is designed to deliver up to six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (CRS) in patients who have not undergone surgery for the disease. Lyra is also developing LYR-220 for CRS patients who have undergone a prior surgery and have persistent disease. Beyond CRS, the company believes its XTreo™ platform, comprised of drug administered through a bioresorbable polymeric matrix, has the potential to address other disease areas by precisely, consistently and locally delivering medicines for sustained periods with a single administration.

To get more information on Lyra Therapeutics Inc and to follow the company's latest updates, you can visit the company's profile page here: Lyra Therapeutics Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Trending Articles

The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation

Market Movers

Sponsored Financial Content